Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,280 people get JAZZ articles and Market Currents by email alert.
Get email alerts on JAZZ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1 -
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11 -
-
-
-
-
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012 -
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Jazz Pharmaceuticals Still in TroubleEben Tessari • Thu, Jun 12, 2008
-
-
-
ISM Leads Market Down Bearish PathDavid Brown • Mon, Apr 1
-
-
Intermarket Trends Favor More Upside For StocksONeil Trader • Mon, Mar 11
-
-
-
-
4 Mid Caps Raking In Profits And Projected For GrowthZetaKap • Mon, Oct 1, 2012
-
-
-
-
-
-
-
-
-
3 Growth Mid Cap Stocks To ConsiderSupreme Alpha • Wed, Aug 22, 2012 -
-
-
Jazz Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, May 5, 2010
-
Jazz Pharmaceuticals Inc. Q2 2008 Earnings Call TranscriptFri, Aug 8, 2008
-
Jazz Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
at CNBC.com (Apr 26, 2013)
-
at CNBC.com (Mar 19, 2013)
-
at MarketWatch.com (Mar 12, 2013)
-
at CNBC.com (Mar 5, 2013)
-
at MarketWatch.com (Oct 2, 2012)
-
at CNBC.com (Aug 15, 2012)
-
at CNBC.com (May 22, 2012)
-
at MarketWatch.com (Feb 7, 2012)
-
at MarketWatch.com (Jan 24, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
at MarketWatch.com (Jan 6, 2012)
-
PR Newswire (Jan 5, 2012)
-
PR Newswire (Dec 12, 2011)
-
at CNBC.com (Sep 21, 2011)
-
at CNBC.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 20, 2011)
-
at MarketWatch.com (Sep 19, 2011)
-
at MarketWatch.com (Sep 8, 2011)
-
at MarketWatch.com (Sep 7, 2011)
JAZZ vs. ETF Alternatives
Company Description
We are a specialty pharmaceutical company that, since our inception, has focused on the development and commercialization of pharmaceutical products to meet important unmet medical needs in neurology and psychiatry. With our JZP-6 product candidate for the treatment of fibromyalgia, for which we... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 12:26 PM Jazz Pharmaceuticals (JAZZ -10%) gets slammed in spite of a solid Q1 earnings beat late yesterday, as investors focus on potential changes at the FDA which could lead the way to approving a generic version of JAZZ's narcolepsy medicine Xyrem, which is currently being produced by Roxane. Xyrem generated $117.5M in sales this quarter alone, nearly 60% of its revenue. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, May 7, 4:15 PM Jazz Pharma (JAZZ): Q1 EPS of $1.37 beats by $0.02. Revenue of $196.2M beats by $. Shares +5.1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Tuesday, May 7, 12:10 AM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GA, GPOR, HTA, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
- Monday, May 6, 5:35 PM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GTEK, GA, GPOR, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
- Tuesday, February 26, 4:35 PM More on Jazz Pharma (JAZZ): Q4 EPS easily beats estimates. Net sales of Xyrem were $113.5M, compared to net sales of $71.8M for Q411. Gross margin was 85.8% compared to 95.2% for 2011. For FY13, the company expects an EPS of $5.70-5.90 on sales of $805M - 835M, above Street estimates of $5.67 on revenue of $811.3M. Shares +2% AH. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, February 26, 4:07 PM Jazz Pharmaceuticals (JAZZ): Q4 EPS of $1.53 beats by $0.12. Revenue of $183.7M misses by $0.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, February 26, 12:10 AM Notable earnings after Tuesday’s close: AVGO, AWK, DGI, DWA, EIX, FSLR, GA, GPOR, GWRE, HRZN, JAZZ, MAKO, MIDD, NUVA, ORA, PCLN, QCOR, RENN, REXX, RRC, SPN, STEC, TIVO, VNO, VRSK, ZAGG Comment! [Earnings]
- Monday, February 25, 5:35 PM Notable earnings after Tuesday’s close: AVGO, AWK, DGI, DWA, EIX, FSLR, GA, GPOR, GWRE, HRZN, JAZZ, MAKO, MIDD, NUVA, ORA, PCLN, QCOR, RENN, REXX, RRC, SPN, STEC, TIVO, VNO, VRSK, ZAGG Comment! [Earnings]
- Thursday, November 8, 2012, 4:22 PM Jazz Pharmaceutical (JAZZ): $1.29 misses by $0.03. Revenue of $175M misses by $4M. Shares -1% AH. (PR) 1 Comment [Healthcare, Earnings, On the Move]
- Thursday, November 8, 2012, 12:10 AM Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP Comment! [Earnings]
- Wednesday, November 7, 2012, 5:35 PM Notable earnings after Thursday’s close: AFFY, AGO, CBOU, CUBE, DAR, DGIT, DIS, DLB, DNN, EGLE, EVEP, GRPN, HALO, HOGS, IGT, IO, JAZZ, JWN, LGF, MCHP, MDRX, MKL, NVDA, PSA, RNDY, SD, SPRD, SQNM, UBNT, WPRT, WR, ZGNX, ZIP Comment! [Earnings]
- Tuesday, August 7, 2012, 4:44 PM More on Jazz Pharmaceuticals (JAZZ): Q2 beats across the board. Total revenues were $129.5M, boosted by strong organic growth and the positive impact of the Azur Pharma and EUSA Pharma acquisitions. The company guided FY12 revenues higher, now expecting revenue of $605M - $615M, versus the current consensus of $599.6M. Comment! [Healthcare, Earnings]
- Tuesday, August 7, 2012, 4:19 PM Jazz Pharmaceuticals (JAZZ): Q2 EPS of $1.09 beats by $0.04. Revenue of $130M beats by $5M. Shares +2.4% AH. Comment! [Earnings, On the Move]
- Tuesday, August 7, 2012, 12:10 AM Notable earnings after Tuesday’s close: ANV, AONE, ARRY, ATLS, BID, CODI, CREE, DIS, DPM, ENOC, ESRX, ETE, ETP, EXM, GPOR, JAZZ, JIVE, MIPS, PCLN, PRI, RAX, SAPE, STEC, VVUS, WFR, WR, XL, Z Comment! [Earnings]
- Monday, August 6, 2012, 5:35 PM Notable earnings after Tuesday’s close: ANV, AONE, ARRY, ATLS, BID, CODI, CREE, DIS, DPM, ENOC, ESRX, ETE, ETP, EXM, GPOR, JAZZ, JIVE, MIPS, PCLN, PRI, RAX, SAPE, STEC, VVUS, WFR, WR, XL, Z 1 Comment [Earnings]
- Tuesday, May 8, 2012, 5:04 PM Jazz Pharmaceuticals (JAZZ): Q1 EPS of $0.91 beats by $0.01. Revenue of $108M (+113% Y/Y) beats by $5.5M. (PR) Comment! [Earnings]
-
Capitalist Bull
Not much left to do, few setups remain. Patiently hold leading growth stocks through 1st pullbacks. http://stks.co/bV7p $ES_F $JAZZ $OCN - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
-
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 3 replies
-
-
-
smokeyRose
What is up with $JAZZ ?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????? - View all 2 replies
-
-
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
- View all 2 replies
-
tippycanoes: I bought under a dollar...sold at 6$... it haunts me. Literally could have retired -
-
- View all 14 replies
-
-
-
Michael Bryant
Jazz Pharmaceuticals (JAZZ) keeps rising. Could be good longterm holding. http://yhoo.it/yGLaZa;c= - View all 2 replies
-
-
-
- View all 5 replies
-
-
SlingWing9: They've all got lawsuits against them. All of them have legal depts, all allocate billions/yr for legal issues. Find one TBTF w/o lawsuits
-
- View all 1 replies
-
losbronces: And that is why people still play biotechs even though the odds of success are low.
-
- View all 3 replies
-
-
-
Michael Bryant
Not bad. Jazz Pharma (JAZZ) up 2%. Ulta Salon (ULTA) up 3.27%. Cabot Oil & Gas (COG) up 0.13%. http://seekingalpha.com/a/6rmy - View all 3 replies
-
-
-
- View all 1 replies
-
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.
-
Michael Bryant
Jazz Pharmaceuticals (JAZZ) is rising on unusual volume. It is a definite buy. PE ratio is very low. - View all 2 replies
-
-